Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized (Q40489054)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized |
scientific article |
Statements
1 reference
Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized (English)
1 reference
Robert M Rifkin
1 reference
Stephanie A Gregory
1 reference
Ann Mohrbacher
1 reference
Mohamad A Hussein
1 reference
1 February 2006
1 reference
1 reference
106
1 reference
4
1 reference
848-858
1 reference
1 reference
Identifiers
1 reference
1 reference